Switch theme
Sign up to access all valuation multiples
Empreendimentos Pague Menos SA operates a pharmacy chain in Brazil. It engaged in the retail trade of medicines, perfumes, personal hygiene, and beauty products. It revenues arises mainly from the sale of medicines, perfumes, and several self-service products to the end consumer.
1981
n/a
LTM Revenue $2.3B
LTM EBITDA $150M
$955M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pague Menos has a last 12-month revenue of $2.3B and a last 12-month EBITDA of $150M.
In the most recent fiscal year, Pague Menos achieved revenue of $2.2B and an EBITDA of $167M.
Pague Menos expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pague Menos valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.0B | $2.2B | XXX | XXX | XXX |
| Gross Profit | $514M | $618M | XXX | XXX | XXX |
| Gross Margin | 26% | 28% | XXX | XXX | XXX |
| EBITDA | $139M | $167M | XXX | XXX | XXX |
| EBITDA Margin | 7% | 8% | XXX | XXX | XXX |
| Net Profit | $45.9M | $0.4M | XXX | XXX | XXX |
| Net Margin | 2% | 0% | XXX | XXX | XXX |
| Net Debt | $248M | $209M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Pague Menos's stock price is BRL 3 (or $1).
Pague Menos has current market cap of BRL 2.1B (or $370M), and EV of BRL 5.5B (or $955M).
See Pague Menos trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $955M | $370M | XXX | XXX | XXX | XXX | $0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Pague Menos has market cap of $370M and EV of $955M.
Pague Menos's trades at 0.4x LTM EV/Revenue multiple, and 6.4x LTM EBITDA.
Analysts estimate Pague Menos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pague Menos and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $955M | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | 5.7x | XXX | XXX | XXX |
| P/E | 20.6x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | 19.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPague Menos's NTM/LTM revenue growth is 10%
Pague Menos's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Pague Menos's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pague Menos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pague Menos and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 18% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 24% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 27% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| Alibaba Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pague Menos acquired XXX companies to date.
Last acquisition by Pague Menos was XXXXXXXX, XXXXX XXXXX XXXXXX . Pague Menos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pague Menos founded? | Pague Menos was founded in 1981. |
| Where is Pague Menos headquartered? | Pague Menos is headquartered in Brazil. |
| Is Pague Menos publicy listed? | Yes, Pague Menos is a public company listed on BVMF. |
| What is the stock symbol of Pague Menos? | Pague Menos trades under PGMN3 ticker. |
| When did Pague Menos go public? | Pague Menos went public in 2020. |
| Who are competitors of Pague Menos? | Similar companies to Pague Menos include e.g. MedPlus India, Droga Raia, Redcare Pharmacy, Oriola. |
| What is the current market cap of Pague Menos? | Pague Menos's current market cap is $370M |
| What is the current revenue of Pague Menos? | Pague Menos's last 12-month revenue is $2.3B. |
| What is the current EBITDA of Pague Menos? | Pague Menos's last 12-month EBITDA is $150M. |
| What is the current EV/Revenue multiple of Pague Menos? | Current revenue multiple of Pague Menos is 0.4x. |
| What is the current EV/EBITDA multiple of Pague Menos? | Current EBITDA multiple of Pague Menos is 6.4x. |
| What is the current revenue growth of Pague Menos? | Pague Menos revenue growth between 2023 and 2024 was 13%. |
| Is Pague Menos profitable? | Yes, Pague Menos is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
